Discontinued — last reported Q4 '20
McKesson Business Sale Proceeds decreased by 96.9% to $4.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 140.0%, from -$10.00M to $4.00M. Over 3 years (FY 2022 to FY 2025), Business Sale Proceeds shows a downward trend with a -32.3% CAGR.
An increase signals portfolio optimization or a strategic pivot, while a lack of proceeds suggests a stable, long-term asset base.
This metric represents the cash inflows received from the divestiture or sale of business segments, product lines, or su...
Occurs sporadically; peers often divest legacy segments to focus on high-margin innovation areas like continuous glucose monitoring or diagnostics.
proceeds_from_sale_of_business| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $83.00M | $96.00M | $18.00M | $381.00M | $240.00M | $256.00M | $578.00M | $3.00M | $39.00M | $11.00M | -$3.00M | $0.00 | $90.00M | $3.00M | -$10.00M | $96.00M | $4.00M | $129.00M | $4.00M |
| QoQ Change | — | +15.7% | -81.3% | >999% | -37.0% | +6.7% | +125.8% | -99.5% | >999% | -71.8% | -127.3% | +100.0% | — | -96.7% | -433.3% | >999% | -95.8% | >999% | -96.9% |
| YoY Change | — | — | — | — | +189.2% | +166.7% | >999% | -99.2% | -83.8% | -95.7% | -100.5% | -100.0% | +130.8% | -72.7% | -233.3% | — | -95.6% | >999% | +140.0% |